Amgen CEO named PhRMA board chairman

9 February 2018

The man in charge at Amgen (Nasdaq: AMGN) has been named the new chairman of the PhRMA board of directors for the year to come.

Robert Bradway, chairman and chief executive at the US biotech major, takes the prominent role at the leading US trade group at the start of a year when the industry faces more questions than ever on value, with President Donald Trump threatening to act on his vow to crack down on high prices.

"I look forward to working with stakeholders across the healthcare system to develop market-based solutions to help fuel this incredible innovation and address patient access and affordability challenges"

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK